We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · November 20, 2019

Canagliflozin Prevents Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c

Circulation

 

Additional Info

Circulation
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial
Circulation 2019 Nov 11;[EPub Ahead of Print], CP Cannon, V Perkovic, R Agarwal, J Baldassarre, G Bakris, DM Charytan, D de Zeeuw, R Edwards, T Greene, HJL Heerspink, MJ Jardine, A Levin, JW Li, B Neal, C Pollock, DC Wheeler, H Zhang, B Zinman, KW Mahaffey

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading